Endometriosis Treatment Market to grow at a CAGR of 13.5% during 2025 to 2035; Driven by Rising Prevalence of Endometriosis and Increasing Demand for Advanced Treatment

Endometriosis Treatment Market Highlights

Endometriosis Treatment Market size was valued at USD 2,126.10 Million in 2024, and the market is projected to grow from USD 2,384.84 Million in 2025 to USD 8,427.32 Million by 2035, registering a CAGR of 13.5% during the forecast period 2025–2035.

MRFR recognizes the following companies as the key players in the endometriosis treatment market— Akorn, Incorporated (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.),Novartis AG (Switzerland), Mylan N.V. (U.S.),Teva Pharmaceutical Industries Ltd.(Israel),Sanofi (France).

The endometriosis treatment market is driven by a rising prevalence of endometriosis cases, increasing awareness, and advances in medical research. Opportunities arise from a growing demand for personalized therapeutics. Challenges include the complexity of the disease, delayed diagnosis, and limited treatment options.

Regulatory scrutiny and the need for effective non-invasive treatments also pose challenges. The market's growth is restrained by these challenges, emphasizing the necessity for ongoing research and innovative solutions.

Segment Analysis

The endometriosis treatment market has been segmented based drug, treatment type and distribution channel.

On the basis of drug, the market is segmented into Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, LNR-IUDs. The oral contraceptives are segment was attributed to holding the largest market share in 2022. Oral contraceptives are widely favored for their ability to control hormonal fluctuations, alleviate pain, and manage the advancement of endometriosis. Additionally, the most rapidly expanding category is GnRH Analogues, as they effectively suppress ovarian function and lower estrogen levels, thus easing endometriosis symptoms.

Based on treatment type, the treatment type market has been segmented into Hormonal Therapy, Pain Management. The hormonal therapy segment was expected to hold the largest market share in 2022. Hormonal therapy, such as oral contraceptives and GnRH analogues, is commonly recommended for its ability to manage hormonal imbalances, reduce pain, and regulate the advancement of endometriosis.

Pain management is the rapidly expanding area in endometriosis care, gaining attention for its crucial role in addressing the condition. As the focus on improving the quality of life for those with endometriosis grows, new pain management approaches and medications are being more widely embraced to alleviate the frequently severe pain linked to the condition.

Based on treatment type, the Distribution Channel market has been segmented into Hospital Pharmacies, Retail Pharmacies, Drugstores, e-Commerce. The hospital pharmacies segment was expected to hold the largest market share in 2022. Hospital pharmacies are essential for providing medications and supporting treatment plans recommended by healthcare providers.

Meanwhile, the e-Commerce sector is expanding at a rapid pace, particularly in the distribution of endometriosis treatment goods. This expansion is driven by the growing preference for convenient, private, and diverse product options through online channels.

Regional Analysis

The endometriosis treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe endometriosis treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The endometriosis treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World endometriosis treatment market comprises of Middle East, Africa, and Latin America.

The largest market share for endometriosis treatment was maintained by the North American regional sector.This increase is attributed to there is a heightened awareness of women's health issues, leading to increased diagnosis and treatment-seeking behavior.

Secondly, advanced healthcare infrastructure and research facilities enable the development and adoption of cutting-edge treatments. Additionally, proactive initiatives, advocacy efforts, and a favorable reimbursement landscape contribute to the dominance of North America in the endometriosis treatment market.

Moreover, the Europe market has been persistently growing over the forecast period. The demand for endometriosis treatment is driven due to the region has a substantial and aging population, contributing to an increased prevalence of endometriosis cases.

Secondly, there is an emphasis on women's health and comprehensive healthcare services in Europe, leading to improved awareness and early diagnosis. Additionally, well-established healthcare infrastructure, coupled with supportive regulatory frameworks, facilitates the development and adoption of advanced treatment options.

Additionally, The Asia-Pacific region is anticipated to experience the quickest growth in the endometriosis treatment market over the forecast period due to several key factors. Firstly, the region has a large and rapidly growing population, leading to an increased prevalence of endometriosis cases.

Secondly, rising awareness about women's health issues and an evolving healthcare infrastructure contribute to improved diagnosis rates and treatment-seeking behavior. Additionally, there is a growing acceptance of medical interventions and a shift towards seeking timely treatment for endometriosis in the Asia-Pacific region.

Furthermore, the rest of the world's endometriosis treatment market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the increasing awareness, improving healthcare infrastructure, and evolving medical practices in these regions. As healthcare awareness expands, more cases of endometriosis are likely to be diagnosed and treated.

Additionally, efforts to enhance healthcare facilities, collaborate with global pharmaceutical companies, and address women's health issues contribute to the growth. While the prevalence may be lower compared to other regions, the rising focus on women's health and improving healthcare accessibility are driving positive trends in endometriosis treatment across these areas.

Key Findings of the Study

• Global endometriosis prevalence impacts nearly 190 million women, with WHO reporting 10% reproductive-age female population affected.


• Diagnostic delay averages 7–10 years globally, significantly increasing demand for advanced hormonal and minimally invasive treatment options.


• North America holds over 45% global market share in 2024, driven by advanced healthcare infrastructure and R&D investment.


• Europe endometriosis market valued at USD 637.83 Million in 2024, capturing approximately 30% global regional share.